TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.

Lindsey E Roeker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.